The Science

Our novel approach aims to transform blood cancer treatment.

Vor Bio is developing a proprietary platform built on Hematopoietic Stem Cell (HSC) biology, genome engineering, and CAR-T Cells.

Our Approach

Treatment-resistant HSCTs potentially enable curative targeted therapy opportunities for blood cancers

We aren’t inventing new technologies. We’re applying the latest scientific advancements to fight AML in a new way.

The Vor Bio Platform

We are working to cure AML and then go further

Our proprietary platform combines genome engineering, Hematopoietic Stem Cell (HSC) biology, and CAR-T cells to solve urgent unmet medical needs for patients with blood cancers.

Understanding Our Impact

For Patients & Caregivers

Our Investigational Program

Our Investigational Program

We aim to transform treatment by protecting the healthy blood cells and only attacking the cancer cells with targeted therapies post-transplant.

African American Doctor Talking To Patient In Office

Our Clinical Trial

We are currently conducting a clinical trial to further investigate our promising approach.

Two Sisters

Patient / Donor Journey

Our approach genetically edits HSCs from a healthy matched donor to be resistant to targeted therapies in the patient post-transplant.

The Science Behind Our Approach

For Medical Professionals

Science Investigational Aspect Ratio 600 400

Our Investigational Program

By protecting healthy cells, we are aiming to delay or prevent relapse and enable cures for patients with AML and other blood cancers.

Clinical Trials Medical Aspect Ratio 600 400

Clinical Trials

Our Phase 1/2a clinical trial is actively recruiting patients.

Join Our Team

Passion. Fellowship. Humility.

Come be a part of a team that is developing a unique approach to one of medicine’s greatest challenges—eradicating cancer.